hVIVO signs GBP6.8 million deal to test RSV antiviral drug candidate
(Alliance News) - hVIVO PLC on Monday said it has signed a GBP6.8 million contract with a leading Asia-Pacific pharmaceutical company, to test its respiratory synctical virus antiviral drug candidate. Read More